Exelixis Stock Buried By Failed Cancer Drug Study

EXEL stock is dangerously close to annual-low territory

Managing Editor
May 10, 2018 at 10:19 AM
facebook X logo linkedin

Exelixis, Inc. (NASDAQ:EXEL) stock is down 11.8% to trade at $19.13 this morning, after the biotech company's colorectal cancer drug that was tested in combination with Roche's Tecentriq failed late-stage study goals. Exelixis said it will continue to work with Roche in evaluating the treatment on other tumor types. In response to the failed study, RBC and Suntrust Robinson issued price-targets cut on EXEL stock, to $35 and $36, respectively.  

Exelixis stock is on track for its worst single-day loss since September 2017. The equity has now shed 36% in 2018, and is dangerously close to its annual low of $18.03 from May 30. Since mid-February, the shares' 20-day moving average has guided EXEL lower, and a brief rally earlier this month was stymied by their 50-day moving average. 

Analysts remain committed to the biotech stock. Of the seven brokerages covering EXEL, six rate it a "buy" or "strong buy," with not a single "sell" on the books. Furthermore, the security's average 12-month price target sits at $35.17, a 78% premium to the stock's current perch. Continued technical struggles could prompt more analysts to re-think their bullish positions.

In the option pits, traders have been betting bullishly in recent weeks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculative players have bought to open 4,828 calls on EXEL stock in the last 10 days, compared to just 808 puts. This indicates calls have outnumbered puts by a nearly 6-to-1 ratio. An unwinding of these bullish bets could push EXEL lower.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI